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Abstract
Background: Lysophosphatidylcholine (LPC), an atherogenic component of oxidized low-density
lipoprotein, has been shown to induce the attenuation of endothelium-dependent vascular
relaxation. Although benidipine, a dihydropyridine-calcium channel blocker, is known to have
endothelial protective effects, the effects of benidipine on LPC-induced endothelial dysfunction
remain unknown. We examined the effects of benidipine on the impairment of endothelium-
dependent relaxation induced by LPC.
Methods: Benidipine was administered orally to rats and aortas were then isolated. Aortic rings
were treated with LPC and endothelial functions were then evaluated. Additionally, the effects of
benidipine on intracellular calcium concentration ([Ca2+]i) and membrane fluidity altered by LPC in
primary cultured rat aortic endothelial cells were examined. [Ca2+]i was measured using the
fluorescent calcium indicator fura-2. Membrane fluidity was monitored by measuring fluorescence
recovery after photobleaching.
Results: Treatment with LPC impaired endothelial function. Benidipine prevents the impairment
of relaxation induced by LPC. Acetylcholine elicited an increase in [Ca2+]i in fura-2 loaded
endothelial cells. The increase in [Ca2+]i was suppressed after exposure to LPC. Plasma membrane
fluidity increased following incubation with LPC. Benidipine inhibited the LPC-induced increase in
membrane fluidity and impairment of increase in [Ca2+]i.
Conclusion: These results suggest that benidipine inhibited LPC-induced endothelial dysfunction
by maintaining increase in [Ca2+]i. Benidipine possesses membrane stabilization properties in LPC-
treated endothelial cells. It is speculated that the preservation of membrane fluidity by benidipine
may play a role in the retainment of calcium mobilization. The present findings may provide new
insights into the endothelial protective effects of benidipine.
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Background
One of the pathological manifestations in atherosclerosis
is the dysfunction of vascular endothelial cells [1]. Oxi-
dized low-density lipoprotein (ox-LDL) is known to accu-
mulate in atherosclerotic arterial walls [2]. A major
bioactive ingredient of ox-LDL appears to be lysophos-
phatidylcholine (LPC), as this lysolipid can inhibit
endothelium-dependent relaxation (EDR) [3,4]. One
mechanism by which LPC causes impairment of EDR is to
inhibit the release of nitric oxide (NO), which is depend-
ent upon the intracellular calcium concentration ([Ca2+]i)
[3,4]. The mechanism by which LPC interacts with
endothelial cells to facilitate the inhibition of EDR
remains unclear. LPC could inhibit receptor-mediated
increases in [Ca2+]i in human umbilical vein endothelial
cells by direct activation of protein kinase C (PKC) [5].
Activated PKC has been shown to inhibit receptor cou-
pled-IP3 formation and subsequent increases in [Ca2+]i in
response to agonists in endothelial cells [5]. On the other
hand, it has been suggested that LPC induces membrane
perturbation accompanied with receptor-G protein
uncoupling in porcine aortic endothelial cells [6]. LPC has
been shown to increase the fluidity of endothelial cell
membranes and can be cytotoxic to endothelial cells [7,8].
It is possible that increased incorporation of LPC into the
plasma membrane of endothelial cells may induce disrup-
tion of the receptor signal transduction system, thereby
leading to impaired production of NO. These data suggest
that LPC-induced changes may vary depending on the ori-
gin and culture of endothelial cells.
Benidipine hydrochloride (benidipine), a dihydropyrid-
ine-calcium channel blocker, has potent and long-acting
antihypertensive effects [9]. We previously showed that
benidipine has pharmacological properties which
improve endothelial functions in hypertensive or hyperc-
holesterolemic experimental models [10,11]. In cultured
endothelial cells, benidipine inhibits LPC-induced vascu-
lar cell adhesion molecule-1 (VCAM-1) expression, reac-
tive oxygen species (ROS) production and apoptosis [12-
14]. Endothelial cells do not express L-type voltage-
dependent calcium channels, which are the primary tar-
gets of dihydropyridine derivatives [15]. It has been sug-
gested that the effects of benidipine are, in part, due to an
anti-oxidant action or upregulation of endothelial nitric
oxide synthase (eNOS) expression [12-14]. However,
whether benidipine affects the LPC-induced dysfunction
of vascular EDR remains unclear. In the present experi-
ments, the effects of benidipine on the LPC-induced
decrease in EDR in rat aortas were investigated and com-
pared with that of other dihydropyridines. Additionally,
the effects of benidipine on agonist-induced increases in
[Ca2+]i attenuated by LPC were examined. Finally, the
inhibitory potency of benidipine on LPC-induced mem-
brane perturbation was assessed.
Methods
Animals
Male SD rats 7–8 weeks (Japan SLC Inc., Shizuoka, Japan)
were used. All animals were kept at 19–25°C in a 12 hr
light/dark cycle. Food and water were available ad libitum
to all animals. This study was conducted in accordance
with the Standards for Proper Conduct of Animal Experi-
ments of Kyowa Hakko Kirin.
Drugs
Benidipine and amlodipine besilate (amlodipine) were
produced by Kyowa Hakko Kirin. Nifedipine, L-α-lyso-
phosphatidylcholine (C16:0, LPC), L-phenylephrine
hydrochloride (PE), acetylcholine chloride (ACh),
pluronic F-127, phorbol 12-myristate 13-acetate (PMA),
calphostin C and pyrrolidine dithiocarbamate (PDTC)
were purchased from Sigma-Aldrich (St. Louis, MO, USA).
Fura-2 acetoxy methylester was purchased from Wako
Pure Chemical Industries (Osaka, Japan). Ro-31-8220
and phorbol 12, 13-dibutyrate (PDB) were purchased
from Nacalai Tesque (Kyoto, Japan). Butylated hydroxy-
toluene (BHT) was purchased from LKT Laboratories (St.
Paul, MN, USA). 1-Acyl-2-[6-[N-(7-nitro-2-1,3-benzoxa-
diazol-4-yl)amino]hexanoyl]-sn-glycero-3-phospho-
choline (NBD-PC) was purchased from Avanti Polar
Lipids (Alabaster, AL, USA). Ascorbic acid was purchased
from Kanto Kagaku (Tokyo, Japan). Benidipine,
amlodipine and nifedipine were suspended in 0.5% w/v
methylcellulose 400 cP (Wako Pure Chemical Industries)
and administered orally. For the in vitro assay, benidipine,
fura-2 acetoxy methylester, PMA, PDB, Ro-31-8220, cal-
phostin C, PDTC, ascorbic acid and BHT were dissolved in
dimethylsulfoxide (DMSO). LPC was dissolved in etha-
nol. Other chemicals were dissolved in distilled water.
Vascular reactivity following oral administration of 
dihydropyridines
Rats were administered orally with benidipine (4 mg/kg),
amlodipine (4 mg/kg), nifedipine (10 mg/kg) or vehicle
in a volume of 5 mL/kg. The doses of benidipine and
amlodipine used were those employed in a previous study
and found to lower blood pressure in Dahl salt-sensitive
hypertensive rats [16]. The dose of nifedipine used was
selected on the basis of a study by Kubo et al [17]. The
depressor effects of these drugs generally exhibit a steady
state during 60–120 min following administration in rats
[17-19]. Therefore, thoracic aortas were isolated under
sodium pentobarbital anesthesia at 90 min following
administration. Aortas were immediately placed in gassed
(95%O2+5%CO2) Krebs-Henseleit solution comprising
119 mmol/L NaCl, 4.7 mmol/L KCl, 1.2 mmol/L MgSO4,
1.8 mmol/L CaCl2, 1.2 mmol/L KH2PO4, 24.9 mmol/L
NaHCO3 and 11.1 mmol/L glucose, and then cut into 2–
3 mm length rings. Aortic rings were attached to holders
and then placed in an organ bath filled with 20 mL Krebs-Journal of Biomedical Science 2009, 16:57 http://www.jbiomedsci.com/content/16/1/57
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Henseleit solution. Following 60 min equilibration, aortic
rings were incubated with 5 μmol/L LPC or 0.05% ethanol
for 60 min. Tissues were washed three times, and vasore-
laxant responses were measured as previously described
[10]. Rings were contracted to submaximal tone with 1
μmol/L PE and subsequently relaxed using the endothe-
lium-dependent vasodilator ACh (0.001–1 μmol/L). The
percentage was calculated by considering contractions
obtained immediately prior to the addition of ACh as
100%.
Culture of rat aortic endothelial cells
Primary cell cultures of endothelial cells were established
using cells removed from thoracic aortas. Isolation of aor-
tic endothelial cells was performed by scraping following
exposure to 1 mg/mL collagenase (Wako Pure Chemical
Industries) for 60 min. Cells were seeded onto 35 mm
diameter glass base dishes (12 mm diameter glass, Asahi
Techno Glass, Chiba, Japan) in HuMedia-EG2 (Kurabo,
Osaka, Japan) growth medium containing of 2% (v/v)
fetal bovine serum, 10 ng/mL human epidermal growth
factor, 10 μg/mL heparin, 1 μg/mL hydrocortisone, 50 μg/
mL gentamycin and 50 ng/mL amphotericin B according
to the manufacturer's instructions. Cells were cultured at
37°C in humidified atmosphere of 95% air and 5% CO2,
and grown subconfluently 4–7 days after isolation.
Intracellular calcium measurement
It has been reported that LPC inhibits ACh-mediated
vasodilation via inhibition of increases in [Ca2+]i  in
endothelial cells [3,4]. To investigate the effects of
benidipine on LPC-attenuated [Ca2+]iresponses to ACh,
we measured [Ca2+]i in rat aortic endothelial cells. [Ca2+]i
was monitored by measuring the fluorescence (F340/
F380) of fura-2. Cells were treated with 5 μmol/L fura-2
acetoxy methylester and 0.04% pluronic F-127 in Hanks
solution (Nissui Pharmaceutical, Tokyo) for 15 min at
37°C. Cells were washed three times and fluorescence sig-
nals were monitored using an Argus-50 fluorescence spec-
trophotometer (Hamamatsu photonics, Shizuoka, Japan)
at room temperature. Response to 3 μmol/L ACh was
obtained and was then followed by washing. Cells were
incubated with 3 μmol/L LPC or 0.03% ethanol for 30
min followed by washing. After washing, cells were
treated with 3 μmol/L ACh. Changes in responses to ACh
were expressed as percent values. Benidipine (1 or 10
nmol/L) or 0.1% DMSO was simultaneously added with
LPC or ethanol for 30 min to evaluate the effects on ACh-
induced increases in [Ca2+]i. The PKC activators PMA and
PDB, and PKC inhibitors Ro-31-8220 and calphostin C
were also examined in an effort to delineate the involve-
ment of PKC upregulation in LPC-induced endothelial
dysfunction. It has been reported that anti-oxidants can
mimic the action of benidipine as manifested by the inhi-
bition of LPC-induced VCAM-1 expression and ROS pro-
duction [12,13]. Therefore, we included the anti-oxidants
ascorbic acid, PDTC and BHT with LPC to examine the
anti-oxidant effects on LPC-induced endothelial dysfunc-
tion.
Membrane fluidity measurement
To evaluate membrane fluidity, fluorescence recovery
after photobleaching (FRAP) experiments were per-
formed. Cells were treated with 2 μg/L NBD-PC in Hanks
solution for 15 min at 37°C. Cells were washed three
times, and then incubated in the presence of 3 μmol/L
LPC or ethanol for 30 min. Benidipine (10 nmol/L) or
DMSO was added with LPC or ethanol. After three
washes, FRAP experiments utilizing LSM510META (Carl
Zeiss MicroImaging GmbH, Göttingen, Germany) were
performed at room temperature. The fluorescence of a
small area of the labeled cell was photobleached using a
laser beam (excitation: 458 nm 10%, bleaching: 458, 488,
514, 543, 633 nm 100%, iteration: 800). After photob-
leaching, the fluorescent intensity in this bleached area
was recovered by redistribution of the dye. The recovery
percent was calculated one second following the end of
the photobleaching.
Data analysis
All values are expressed as mean ± standard error (S.E.).
Statistical analyses were performed using SAS (SAS Insti-
tute, Inc., Cary, NC). For the comparison between 2
groups, an F-test was employed to evaluate a difference on
variances. The Student's t-test was performed when signif-
icance on variance was not observed. The Aspin-Welch
test was performed when significance on variances was
observed. Differences in multigroup were assessed using
1-way ANOVA and the Dunnett test after confirmation of
significance on variances was not observed by the Bartlett
test. Differences were considered statistically significant at
P < 0.05.
Results
Inhibitory effects of benidipine on LPC-induced 
attenuation of EDR in rat aortas
PE induced contraction and ACh elicited relaxation in iso-
lated muscle strips from rat thoracic aortas (Figure 1A).
ACh-induced relaxation was markedly impaired follow-
ing LPC challenge (Figure 1B, 2A, B and 2C). Orally
administered benidipine inhibited LPC-induced attenua-
tion of EDR (Figure 1C and 2A). In contrast, amlodipine
and nifedipine did not affect LPC-induced attenuation of
EDR (Figure 2B and 2C). Benidipine, amlodipine and
nifedipine did not significantly inhibit PE-induced con-
traction (data not shown).Journal of Biomedical Science 2009, 16:57 http://www.jbiomedsci.com/content/16/1/57
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Tracings showing relaxant response to ACh (endothelium-dependent vasodilator) in isolated rat aorta Figure 1
Tracings showing relaxant response to ACh (endothelium-dependent vasodilator) in isolated rat aorta. 
Benidipine or vehicle was administered orally to rats. Thoracic aortas were isolated at 90 min following benidipine administra-
tion. Aortas were cut into rings, and incubated with LPC (5 μmol/L) or ethanol (0.05%) for 60 min. After washing, the rings 
were pre-contracted using PE (1 μmol/L) and subsequently relaxed using ACh. ACh evoked relaxation in the aortic ring iso-
lated from vehicle-treated rat (A). EDR was markedly attenuated following incubation with LPC (B). LPC-induced attenuation 
of EDR was inhibited in benidipine-treated rat (C).
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Reversal effects of benidipine on LPC-induced suppression 
of [Ca2+]i increase in endothelial cells
In fura-2 loaded endothelial cells, ACh induced an
increase in [Ca2+]i (Figure 3A). The increase in [Ca2+]i was
inhibited by 3 μmol/L LPC (Figure 3B and 4), and the
simultaneous addition of 10 nmol/L benidipine pre-
vented LPC-induced suppression of increases in [Ca2+]i
(Figure 3C and 4). In the absence of LPC, benidipine had
no effect on ACh-induced increases in [Ca2+]i at 1 and 10
nmol/L (Figure 4). The PKC activators PMA and PDB did
not alter ACh-induced increases in [Ca2+]i (Figure 5). The
PKC inhibitors Ro-31-8220 and calphostin C did not
affect the LPC-induced suppression of increases in [Ca2+]i
(Figure 6). The antioxidants ascorbic acid, PDTC and BHT
also did not affect the LPC-induced suppression of
increases in [Ca2+]i (Figure 7).
Effects of benidipine (A), amlodipine (B) and nifedipine (C) on  LPC-induced attenuation of endothelium-dependent relaxa- tion Figure 2
Effects of benidipine (A), amlodipine (B) and nifed-
ipine (C) on LPC-induced attenuation of endothe-
lium-dependent relaxation. Drugs were administered 
orally to rats. Rats were treated as described for Figure 1. 
Data are expressed as percentage of PE-induced contraction. 
Each value represents the mean ± S.E. of 6–10 experiments. 
*P < 0.05 vs. vehicle + LPC group.
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Tracings showing [Ca2+]i (indicated by fluorescence ratio of  fura-2 at 340 nm and 380 nm) transient in rat aortic endothe- lial cells Figure 3
Tracings showing [Ca2+]i (indicated by fluorescence 
ratio of fura-2 at 340 nm and 380 nm) transient in rat 
aortic endothelial cells. ACh (3 μmol/L) elicited increases 
in [Ca2+]i in fura-2-loaded endothelial cells. Vehicles of LPC 
and benidipine had no effect on ACh-induced increases in 
[Ca2+]i (A). LPC (3 μmol/L) decreased ACh-induced 
increases in [Ca2+]i (B). Benidipine (10 nmol/L) prevented 
LPC-induced suppression of increases in [Ca2+]i (C).
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Effects of benidipine with or without LPC on ACh-induced  increases in [Ca2+]i Figure 4
Effects of benidipine with or without LPC on ACh-
induced increases in [Ca2+]i. Endothelial cells were 
treated as described for Figure 3. Benidipine (1 or 10 nmol/L) 
or DMSO was simultaneously added with LPC or ethanol. 
Changes in ACh-induced increases in calcium are expressed 
as percentage fluorescence value of ACh-induced increases 
in calcium prior to LPC or ethanol treatment. Each value rep-
resents the mean ± S.E. of 7 cells. *P < 0.05, **P < 0.01, ***P 
< 0.001 compared between indicated groups.
Benidipine 
11 0 1 10 nmol/L  DMSO
Benidipine 
DMSO



0
50
100
150
200
C
h
a
n
g
e
 
i
n
 
c
a
l
c
i
u
m
 
i
n
c
r
e
a
s
e
 
(
%
) Ethanol
LPC










Benidipine 
11 0 1 10 nmol/L  DMSO
Benidipine 
DMSO



0
50
100
150
200
C
h
a
n
g
e
 
i
n
 
c
a
l
c
i
u
m
 
i
n
c
r
e
a
s
e
 
(
%
) Ethanol
LPC










 
Effects of PKC activators on ACh-induced increases in  [Ca2+]i Figure 5
Effects of PKC activators on ACh-induced increases 
in [Ca2+]i. Fura-2 loaded endothelial cells were treated with 
ACh (3 μmol/L) followed by washing. Cells were then incu-
bated with PMA, PDB or DMSO for 30 min. After washing, 
ACh (3 μmol/L) was added once again. Changes in ACh-
induced increases in calcium are expressed as percentage flu-
orescence value of ACh-induced increases in calcium prior 
to LPC or ethanol treatment. Each value represents the 
mean ± S.E. of 7 cells.
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Effects of PKC inhibitors with or without LPC on ACh- induced increases in [Ca2+]i Figure 6
Effects of PKC inhibitors with or without LPC on 
ACh-induced increases in [Ca2+]i. Fura-2 loaded 
endothelial cells were treated with the protein kinase C 
inhibitors Ro-31-8220 and calphostin C for 30 min. ACh (3 
μmol/L) was added before and after treatment. Data are 
expressed as percentage value of ACh-induced increases in 
calcium prior to treatment. Each value represents the mean 
± S.E. of 7 cells. **P < 0.01, ***P < 0.001 compared between 
indicated groups.
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Effects of anti-oxidants on ACh-induced increases in [Ca2+]i  with LPC Figure 7
Effects of anti-oxidants on ACh-induced increases in 
[Ca2+]i with LPC. Fura-2 loaded endothelial cells were 
treated with the anti-oxidants ascorbic acid, PDTC and BHT 
for 30 min. ACh (3 μmol/L) was added before and after 
treatment. Data are expressed as percentage value of ACh-
induced increases in calcium prior to the treatment. Each 
value represents the mean ± S.E. of 7 cells. ***, P < 0.001 
compared between indicated groups.
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Effects of LPC and benidipine on membrane fluidity
The movement of dye in the FRAP experiment indicated
that LPC increased the membrane fluidity of endothelial
cells. Benidipine at 10 nmol/L normalized membrane flu-
idity in the presence of LPC (Figure 8).
Discussion
In the present study, we demonstrated that LPC inhibited
receptor-mediated EDR and increases in [Ca2+]i  in
endothelial cells. Reduced production of NO in LPC-
treated aorta likely results from inhibition of ACh-
induced increases in [Ca2+]i. Benidipine treatment pre-
vented LPC-induced attenuation of EDR. In endothelial
cells, benidipine prevented LPC-induced attenuation of
increases in [Ca2+]i. These results suggest that benidipine
inhibits LPC-induced impairment of EDR by retainment
of [Ca2+]i mobilization in endothelial cells. The oxidative
stress caused by LPC is postulated to be responsible for the
inhibition of EDR [20]. Endothelial dysfunction is associ-
ated with increased inactivation of NO by the superoxide
anion (O2-) resulting in the formation of peroxynitrite
(ONOO-) [21]. It is known that some dihydropyridine
derivatives can augment NO release from endothelial cells
probably through anti-oxidation [22]. It has been sug-
gested that nifedipine increases the bioavailability of
endothelial NO by reducing the production of ROS [23].
Benidipine is also known to possess antioxidant activity
[24]. Therefore inhibition of ROS production by
benidipine may result in increased bioavailability of NO.
If the anti-oxidative properties of benidipine account for
the inhibition of LPC-induced endothelial dysfunction,
anti-oxidants should restore EDR. Previous reports have
shown that ascorbic acid and PDTC can mimic the action
of benidipine as manifested by the inhibition of LPC-
induced VCAM-1 expression and ROS production
[12,13]. BHT is a lipid-soluble anti-oxidant which pro-
vides protection against experimental atherosclerosis
[25]. In the present study, those antioxidants did not alter
the LPC-induced inhibition of increases in [Ca2+]i. The
lack of effects of the antioxidants suggested that the effects
of benidipine did not emanate from its anti-oxidant activ-
ity.
The precise mechanisms responsible for the inhibitory
effect of LPC on EDR have not been elucidated [3-8].
There is some evidence to suggest that LPC could cause
receptor-G-protein uncoupling [6]. In intact rabbit aorta,
LPC induced attenuation of ACh-mediated increases in
[Ca2+]i [3]. The inhibitory effect of LPC may result from
direct interaction with the plasma membrane of endothe-
lial cells [7,8]. An increase in LPC may alter physiological
properties of the plasma membrane such as membrane
fluidity and permeability [7,8]. This alteration in mem-
brane fluidity may also displace boundary lipids around
integral protein effector systems, which might in turn
interfere with protein structure and enzymatic activities
[26]. On the other hand, it has been reported that PKC
activation by LPC inhibited thrombin-mediated increases
in [Ca2+]i in human umbilical vein endothelial cells [5]. In
our experiment, the PKC inhibitors Ro-31-8220 and cal-
phostin C did not inhibit LPC-induced [Ca2+]i suppres-
sion. The direct PKC activators PMA and PDB had no
effect on ACh-induced increases in [Ca2+]i. These findings
suggest that PKC activation does not account for the inhi-
bition of ACh-induced increases in [Ca2+]i in rat aortic
endothelial cells. We showed that LPC induced significant
increases in membrane fluidity. It was speculated that LPC
probably induces the suppression of ACh-mediated
increases in [Ca2+]i  by increasing membrane fluidity.
However, the mechanism underlying ACh-induced
increases in [Ca2+]i remain unclear. Further studies are
needed to rule out a causal relationship between mem-
brane fluidity and increases in [Ca2+]i.
Benidipine inhibited the LPC-induced suppression of
increases in [Ca2+]i  at 10 nmol/L. LPC significantly
increased relative membrane fluidity. In the presence of
LPC, benidipine preserved an adequate level of mem-
brane fluidity at 10 nmol/L. Benidipine possesses high
liposolubility and affinity for cell membranes compared
with amlodipine and nifedipine [9]. It seems likely that
improved membrane fluidity with incorporated
benidipine accounts for the inhibition by benidipine of
LPC-induced suppression of increases in [Ca2+]i. In the
Effects of benidipine on fluorescence recovery one second  after the end of photobleaching Figure 8
Effects of benidipine on fluorescence recovery one 
second after the end of photobleaching. NBD-PC 
loaded endothelial cells were treated with LPC (3 μmol/L) or 
ethanol (0.03%) for 30 min. Benidipine (10 nmol/L) or DMSO 
was simultaneously added with LPC or ethanol. Each value 
represents the mean ± S.E. (n = 18–28). *P < 0.05 compared 
between indicated groups.
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present study, benidipine exclusively inhibited LPC-
induced attenuation of EDR. It seems that the unique
effects of benidipine are due to its high affinity for the cell
membrane. It has been reported that the maximum
plasma drug concentration of benidipine after oral
administration to rats at a dose of 3 mg/kg, which is an
antihypertensive dosage of spontaneously hypertensive
rats, is 36 nmol/L (19.5 ng/mL) [18,27]. Therefore, the
plasma concentration of benidipine is sufficient to pre-
serve adequate membrane fluidity and associated func-
tional changes in endothelial cells when administered in
antihypertensive dosages.
It has been shown that benidipine inhibits LPC-induced
expression of adhesion molecules, the production of ROS
and apoptosis in endothelial cells [12-14]. The relation-
ship between membrane fluidity and the mechanisms
underlying these LPC-induced endothelial impairments
remain poorly understood. In the present study, we did
not perform the experiments to prove or disprove involve-
ment of membrane perturbation in endothelial impair-
ments. Therefore, the role of membrane stabilization in
the inhibitory effects on LPC-induced endothelial impair-
ment needs to be clarified in future studies.
LPC is associated with ox-LDL and is localized in athero-
sclerotic plaques in high concentrations [1,2]. The lysoli-
pid may play an important atherogenic role during initial
stages of the atherosclerotic process [28]. In endothelial
cells, benidipine inhibits LPC-induced expression of
adhesion molecules, production of ROS and apoptosis, in
addition to impairment of vascular EDR [12-14]. These
endothelial protective effects of benidipine may play an
important role in the mechanism underlying protection
against LPC-induced endothelial dysfunction associated
with the early atherosclerotic process.
Conclusion
Benidipine prevented LPC-induced attenuation of EDR in
rat aorta. In endothelial cells, the LPC-induced decrease in
ACh-mediated calcium mobilization and increase in
membrane fluidity were inhibited by benidipine. From
the present investigation, it is speculated that the inhibi-
tory activity of benidipine against LPC-induced attenua-
tion of EDR is related to its action involving membrane
stabilization.
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